Predicting polycystic ovary syndrome (PCOS) with machine learning algorithms from electronic

- 2 health records3
- Zahra Zad, BS^{1*}; Victoria S. Jiang, MD^{2*}; Amber T. Wolf, BA³; Taiyao Wang, PhD¹; J. Jojo Cheng, BA⁴;
- 5 Ioannis Ch. Paschalidis, PhD^{1,5}; Shruthi Mahalingaiah, MD, MS^{2,6~}
- 6
- ⁷ ¹Division of Systems Engineering, Center for Information and Systems Engineering (CISE), Boston
 - 8 University, 15 St. Mary's Street, Brookline, MA 02446, USA
- ⁹ ²Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology,
- 10 Massachusetts General Hospital, 55 Fruit Street, Yawkey 10, Boston, MA 02114, USA
- ³Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA
- ⁴ Department of Biostatistics and Medical Informatics, University of Wisconsin, West Johnson Street,
 Madison, WI 53792, USA
- ⁵Department of Electrical & Computer Engineering, Department of Biomedical Engineering, and Faculty
- 15 for Computing & Data Sciences, Boston University, 8 St. Mary's Street, Boston, MA 02215, USA
- ⁶Department of Environmental Health, Harvard T.H. Chan School of Public Health, 665 Huntington
- 17 Avenue, Boston, MA 02115, USA
- 18
 * Zahra Zad and Victoria S. Jiang contributed equally to this manuscript and are co-first authors of this
- 20 manuscript.
- 21
- 22 Corresponding Author & reprint requests:
- 23 Shruthi Mahalingaiah, MD, MS. ORCID: 0000-0002-5527-5787
- 24 Email: <u>shruthi@hsph.harvard.edu</u>
- 25
- 26 Study funding/competing interest(s): This study was partially supported by National Science
- Foundation grants CCF-2200052, IIS-1914792, and DMS-1664644, by the NIH under grants R01
- 28 GM135930 and UL54 TR004130, and by the Boston University Kilachand Fund for Integrated Life
- 29 Science and Engineering
- 30
- 31 **Disclosure Summary:** The authors declare no conflict of interest and nothing to disclose.

32 Abstract:

Introduction: Predictive models have been used to aid early diagnosis of PCOS, though existing models are based on small sample sizes and limited to fertility clinic populations. We built a predictive model using machine learning algorithms based on an outpatient population at risk for PCOS to predict risk and facilitate earlier diagnosis, particularly among those who meet diagnostic criteria but have not received a diagnosis.

38

39 Methods: This is a retrospective cohort study from a SafetyNet hospital's electronic health records

40 (EHR) from 2003-2016. The study population included 30,601 women aged 18-45 years without

41 concurrent endocrinopathy who had any visit to Boston Medical Center for primary care, obstetrics and

42 gynecology, endocrinology, family medicine, or general internal medicine. Four prediction outcomes

were assessed for PCOS. The first outcome was PCOS ICD-9 diagnosis with additional model outcomes
 of algorithm-defined PCOS. The latter was based on Rotterdam criteria and merging laboratory values,

radiographic imaging, and ICD data from the EHR to define irregular menstruation, hyperandrogenism,

- 46 and polycystic ovarian morphology on ultrasound.
- 47

48 **Results:** We developed predictive models using four machine learning methods: logistic regression,

49 supported vector machine, gradient boosted trees, and random forests. Hormone values (follicle-

50 stimulating hormone, luteinizing hormone, estradiol, and sex hormone binding globulin) were combined

51 to create a multilayer perceptron score using a neural network classifier. Prediction of PCOS prior to

clinical diagnosis in an out-of-sample test set of patients achieved AUC of 85%, 81%, 80%, and 82%,

respectively in Models I, II, III and IV. Significant positive predictors of PCOS diagnosis across models included hormone levels and obesity; negative predictors included gravidity and positive bHCG.

54 55

56 **Conclusions:** Machine learning algorithms were used to predict PCOS based on a large at-risk

57 population. This approach may guide early detection of PCOS within EHR-interfaced populations to

58 facilitate counseling and interventions that may reduce long-term health consequences. Our model

59 illustrates the potential benefits of an artificial intelligence-enabled provider assistance tool that can be

60 integrated into the EHR to reduce delays in diagnosis. However, model validation in other hospital-based

61 populations is necessary.

62

Keywords: Polycystic ovary syndrome (PCOS), disease prediction, predictive model, machine learning,
 artificial intelligence.

- 65
- 66 Word count: 5,712
- 67

68 **Number of figures and tables:** 7 (& 7 supplementary tables)

69 Introduction

Polycystic ovary syndrome (PCOS) is the most common type of ovulation disorder and
 endocrinopathy among reproductive age women. PCOS is a diagnosis of exclusion after other
 endocrinopathies known to affect ovulation have been evaluated including thyroid, adrenal, and pituitary
 related disease. Based on the Rotterdam criteria, PCOS is diagnosed when two of the three following
 criteria are exhibited: clinical or biochemical hyperandrogenism, oligo-anovulation, and polycystic ovary
 morphology (PCOM) on transvaginal or transabdominal ultrasound. PCOS has a population prevalence of
 5-15%, depending on the diagnostic criteria used (1).

PCOS is associated with multiple health issues and increased morbidity and mortality, including a high chronic disease burden that is also very costly for individuals with PCOS and insurers (2). PCOS is the leading cause of anovulatory infertility in reproductive-aged women. In fact, over 90% of anovulatory

- women who present to infertility clinics have PCOS (3). PCOS patients have an increased risk of
 endometrial hyperplasia and endometrial cancer (4) due to anovulatory cycles leading to long periods of
- exposure to the effects of unopposed estrogen. PCOS has been associated with the development of
- metabolic syndrome (5), diabetes (6), cerebrovascular disease and hypertension (7), compared to women
- 84 without PCOS. Despite these serious health consequences, PCOS frequently goes undiagnosed due to the
- 85 wide range of symptom severity on presentation, leading to delayed treatment and potentially more severe
- clinical sequelae due to lack of preventive care, health management, and counseling (4). Even when
- PCOS is diagnosed, it is often very delayed. One study found that over one-third of women with PCOS
 waited over two years and were seen by three or more providers before finally receiving the diagnosis (8).

Predictive models can play a significant role in aiding earlier diagnosis of PCOS, though several include only those women presenting for fertility care. One model used serum anti-Müllerian hormone (AMH) and androstenedione levels, menstrual cycle length, and BMI to predict the development of PCOS in Chinese women (9). Another model used only AMH and BMI to predict a diagnosis of PCOS or other ovulatory dysfunction disorders (10). Other studies have created predictive models for certain outcomes

ovulatory dysfunction disorders (10). Other studies have created predictive models for certain outcomes
 among women with PCOS such as pregnancy outcomes (11,12) and insulin resistance (13). In this study,

- 95 we use clinical and socioeconomic variables among 30,601 women aged 18 to 45 years within the
- 96 electronic health records (EHR) to develop predictive model utilizing machine learning algorithms with
- 97 the goal of earlier detection and treatment of PCOS.
- 98

99 Materials and Methods

100 Data acquisition

101 The dataset was created by querying de-identified patient data from female patients aged 18 to 45 102 years who had or were considered at risk for PCOS diagnosis by having had any one of the three testing 103 procedures for PCOS in their EHR. Included within the initial sample were those patients who had any 104 visit to Boston Medical Center (BMC) for primary care, obstetrics and gynecology, endocrinology, family 105 medicine, or general internal medicine and received: 1) a pelvic/transvaginal ultrasound for any reason, 2) 106 androgen lab assessment, or had clinical symptoms of androgen excess, 3) an ICD-9 label for irregular 107 periods, or 4) a PCOS diagnosis, between October 2003 to December 2016 within the BMC Clinical Data 108 Warehouse (CDW). The start-date was selected to reflect the first day that ICD-9 codes were used and

- 109 recorded at BMC. The end date reflected cessation of use of the ICD-9 codes and transition to ICD-10
- 110 codes within BMC. To avoid misidentifying an ovulation disorder caused by another endocrinopathy,
- 111 exclusion criteria included diagnosis of concurrent endocrinopathy, such as thyroid disorders,
- 112 hyperaldosteronism, Cushing's syndrome, other adrenal gland disorders, or malignancy based on ICD-9
- codes as listed in Supplementary Table 1.

115 Ethical approval

116 The study was approved by the Institutional Review Board of Boston University School of 117 Medicine and the Harvard T.H. Chan School of Public Health (Protocol # H35708) and is considered

- 118 non-human subjects research.
- 119

120 **Reference label definitions**

121 Individual predictors

122 Time-varying predictor variables with a date stamp before that of the outcome of interest were 123 included in our models. We considered the following predictor variables:

Socioeconomic and lifestyle demographic variables: age, race (White/Caucasian, Black/African
 American, Hispanic/Latina, Asian, Native Hawaiian/Pacific Islander, Middle Eastern, Other/Unknown),
 smoking status (yes/no), marital status (single, married, separated, divorced, widowed, other),
 homelessness (yes/no), and highest level of education (8th grade or less, some high school, high school
 graduate, some college/technical/vocational training, graduated college/technical school/vocational

129 training, declined to answer, other).

130Anthropometrics: Body mass index (BMI, kg/m²) was either calculated from height and weight or131abstracted as the listed BMI variable associated with each visit. BMI was then categorized into three132categories: normal (BMI < 25 kg/m²); overweight (BMI between 25-30 kg/m²); and obese (BMI > 30133kg/m²). To further capture the obesity population in the absence of height/weight/BMI data, the obese134category also included any patient with an ICD-9 code for unspecified obesity (278.00), morbid obesity135(278.01), localized adiposity (278.1), and/or a history of gastric bypass.

136 Cardiovascular health: To include blood pressure as a predictor variable, we defined a 137 categorical hypertension variable by using systolic (SBP) and diastolic (DBP) blood pressure readings and ICD-9 diagnostic codes for unspecified essential hypertension (401.9), benign essential hypertension 138 139 (401.1), and essential primary hypertension (401.0). Blood pressure was categorized into three groups: 140 normal, defined by no ICD-9 codes for hypertension recorded and SBP < 120 mmHg, and DBP < 80 141 mmHg; elevated, defined by no ICD-9 codes for hypertension recorded and SBP was 120-129 mmHg or 142 DBP < 80 mmHg; hypertension, defined by any ICD-9 code for hypertension recorded or SBP > 140143 mmHg or DBP > 90 mmHg.

144 Reproductive endocrine predictive variables: beta human chorionic gonadotropin (bHCG) level 145 (negative bHCG < 5 mIU/mL, positive bHCG ≥ 5 mIU/mL), HIV status (negative/positive), age at 146 menarche, pelvic inflammatory disease diagnosis (614.9), history of hysterosalpingogram, and gravidity 147 (history of present or prior pregnancy within obstetric history). Endocrine and metabolic lab values 148 included: TSH, glycosylated hemoglobin (A1c) as a marker for diabetes, low-density lipoprotein (LDL), 149 high density lipoprotein (HDL), and diagnosis of hypercholesterolemia (272.0). Of note, our model did 150 not include androgen precursors such as DHEA or androstenedione as, according to Monash guidelines, 151 these values provide limited additional information in the diagnosis of PCOS (14,15). 152

153 **Combined predictors**

Expecting a nonlinear relationship between many reproductive hormones and a PCOS diagnosis, we used a multilayer perceptron (MLP) neural network to map follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormone binding globulin (SHBG), and estradiol (E2) values to a composite metric we call MLP score. The MLP score was repetitively trained and the hyperparameters were tuned to generate a predictive probability associated with PCOS diagnosis for each predictive model, as described with further detail below.

160

161 Outcomes

162 *Defining PCOS:* PCOS diagnosis was assigned for any patient who had an ICD-9 code for PCOS 163 (256.4) or met the Rotterdam criteria (16), according to which a positive diagnosis is made in the 164 presence of two out of the following three features: (i) irregular menses (IM) as defined by rare menses, 165 oligo-ovulation, or anovulation; (ii) hyperandrogenism (HA) as defined by clinical or biochemical 166 androgen excess; and (iii) polycystic ovarian morphology (PCOM) noted on transabdominal or

167 transvaginal ultrasound. Based on these three criteria, we defined three auxiliary variables IM, HA, and

168 PCOM to use in the definition of our labels. PCOM was captured through diagnostic radiology text

169 reports from ovarian ultrasound imaging for the subset that had ultrasound imaging (17).

170 *Defining Irregular Menstruation (IM):* IM was defined with the following ICD-9 codes: absence 171 of menstruation (626.0), scanty or infrequent menstruation (626.1), irregular menstrual cycle (626.4), 172 unspecified disorders of menstruation and abnormal bleeding from female genital tract (626.9), and 173 infertility, female associated with anovulation (628.0) (3).

174 *Defining Hyperandrogenism (HA):* HA was assigned to a patient if any of the androgen lab 175 testing for bioavailable testosterone, free testosterone, or total testosterone was greater than clinical 176 thresholds of 11 ng/dL, 5 pg/mL, 45 ng/dL, respectively. In addition, HA was assigned if ICD-9 codes 177 for hirsutism (704.1) or acne (706.1 or 706.0) were recorded for a patient.

178 *Defining Ultrasound characteristics for polycystic ovarian morphology (PCOM):* Among those 179 with an ultrasound in this dataset, PCOM was identified on ultrasound reports using natural language 180 processing (NLP) with complete methods detailed by Cheng and Mahalingaiah (17), to report PCOM as

identified (PCOM present), unidentified (PCOM absent), or indeterminate (PCOM unidentifiable based
 on source report data).

183 We considered four models to predict the following: Model I: patients with ICD-9 diagnosis of 184 PCOS (256.4) within the EHR; Model II: patients diagnosed with PCOS by Rotterdam criteria having IM 185 and HA without a specific ICD-9 PCOS code; Model III: patients diagnosed with PCOS by Rotterdam 186 criteria having two out of the three conditions IM/HA/PCOM and without a specific ICD-9 PCOS code; 187 Model IV: all patients with PCOS using either Model I or Model III criteria. ICD-9 codes were abstracted 188 from the billing code and diagnosis code associated with each encounter within the EHR. Model I 189 included all patients who were diagnosed with PCOS. Model II and its superset Model III was composed 190 of patients who did not have a PCOS diagnosis code but met diagnostic criteria of PCOS based on 191 Rotterdam criteria, representing the patient population with undiagnosed PCOS. Model IV essentially 192 captures all women who were diagnosed or met criteria for PCOS within our population. Supplementary 193 Table 2 details model definitions and includes the count and percent of patients in each category. The date 194 of diagnosis was assigned by the date of PCOS ICD-9 code (256.4) for Model I, the date of the latest 195 diagnostic criteria met for Model II and III, and the earlier date associated with Model I and Model III, for 196 Model IV.

196 Mo 197

198 **Predictive models**

199 Classification methods

200 We explored a variety of supervised classification methods, both linear and nonlinear. Linear 201 methods included logistic regression (LR) and support vector machines (SVM) (18) and were fitted with 202 an additional regularization term: an L1-norm of the coefficient vector to inject robustness (19) and induce sparsity. Regularization added a penalty to the objective function, thereby minimizing the sum of a 203 204 metric capturing fitness to the data and a penalty term that is equal to some multiple of a norm of the 205 model parameters. Sparsity was motivated by the earlier works (20–23), where it was shown that sparse 206 classifiers can perform almost as well as very sophisticated classification methods. Nonlinear methods, 207 including gradient boosted trees (GBT/XGBoost) (24) and random forests (RF) (25) which produce large 208 ensembles of decision trees, may yield better classification performance, but are not interpretable or 209 explainable to enable a safety check by a clinician. Specifically, the RF is a large collection of decision 210 trees and it classifies by averaging the decisions of these trees. The GBT/XGBoost, also called gradient 211 boosting machine (GBM), similarly combines decisions by many decision trees. We used LightGBM 212 which is a fast, high-performance GBM framework (26). We tuned GBM's hyperparameters through 213 cross-validation.

214

215 **Performance metrics**

To assess model performance, we obtained the Receiver Operating Characteristic (ROC) curve. The ROC is created by plotting the true positive rate, which is indicative of sensitivity or recall, against the false positive rate (equal to one minus specificity) at various thresholds. The c-statistic or the area under the ROC curve (AUC), is used to evaluate the prediction performance. A perfect predictor is

defined by generating an AUC score of 1, and a predictor which makes random guesses has an AUC score of 0.5. We also used the weighted-F1 score to evaluate the models. The weighted-F1 score is the average of the F1 scores of each class weighted by the number of participants in each class. The classspecific F1 scores are computed as the harmonic mean of precision and recall of a classifier which predicts the label of the given class. The weighted-F1 score is between 0 to 1, and a higher value represents a better model. The AUC is more easily interpretable, and the weighted F1-score is more robust to class imbalance (27).

227

228 Statistical feature selection (SFS)

229 Categorical variables were converted into dummy/indicator variables. To avoid collinearity, we 230 dropped the missing or unclassified data (NaN) category. For continuous variables, missing values were 231 imputed by the median value for that variable. A summary of the missing variables for each model is 232 provided in Supplementary Table 3. Variables with very low variability (SD<0.0001) were assessed for 233 removal from the models, however none were noted in any model. We applied statistical feature selection 234 (SFS) to reduce the less informative features and simplify the models. For each of the four models' 235 outcomes, the chi-squared test was applied for binary variables and the Kolmogorov-Smirnov statistic for 236 continuous variables; the variables for which we could not reject the null hypothesis of the same 237 distribution for each class (p-value >0.01) were removed. Representative aggregated patient-level 238 statistics for each model are shown in Supplementary Table 4. We also removed one from each pair of 239 highly correlated variables (with absolute value of the correlation coefficient > 0.8) to avoid redundant 240 variables. Highly correlated variables and the retained variable are provided in Supplementary Table 5. 241 For all models we standardized the corresponding features by subtracting the mean and scaling to unit 242 variance.

242 v 243

244 **Training-test splitting**

We split the dataset into five random parts, where four parts were used as the training set, and the remaining part was used for testing. We used the training set to tune the model hyperparameters via 5-fold cross-validation, and we evaluated the performance metrics on the testing set. We repeated training and testing five times, each time with a different random split into training/test sets. The mean and standard deviation of the metrics on the test sets over the five repetitions are reported.

250

251 **Development of the MLP score**

252 For every model, there was a considerable difference between the AUC of linear models and non-253 linear models. To improve the performance of our linear models, we utilized nonlinear models to capture 254 intricate relationships between features. We utilized Gradient Boosted Trees (GBT) to find which features 255 most commonly appeared together among decision trees. We found FSH, LH, SHBG, and estradiol levels 256 to be a meaningful group of features which are all reproductive hormones and continuous variables that 257 appeared together among trees for all our models. We subsequently used these four features as input 258 features into a multilayer perceptron (MLP) neural network model with three hidden layers, each 259 employing the rectified linear unit (ReLU) activation function. The neural network was trained using the 260 training set to classify PCOS. We used the output probability of the MLP model, which we called "MLP 261 score," as a new feature into our original predictive models.

262

263 **Recursive feature elimination (RFE)**

We also used a recursive feature elimination approach with L1-penalized logistic regression (L1regularized RFE) to extract the most informative features and develop parsimonious models. Specifically, after running the L1-penalized logistic regression (L1-LR), we obtained weights associated with the variables (i.e., the coefficients of the model, denoted by β), and we eliminated the variable with the smallest absolute weight in each turn. We iterated in this fashion, eliminating one variable at a time, to select a model that maximizes a metric equal to the mean AUC minus the standard deviation (SD) of the

AUC in a validation dataset (using 5-fold cross-validation on the training set to obtain an average of this metric over five repetitions).

272

273 Final predictive models

We computed the performance of the following models: L1-penalized logistic regression (LR-L1), support vector machine (SVM-L1), random forests (RF), and gradient boosted trees

276 (GBT/XGBoost). We calculated each variable's LR coefficient with a 95% confidence interval (β

[95%CI]), the correlation of the variable with the outcome (Y-correlation), the p-value of each variable

(p-value), the mean of the variable (Y1-mean) in the PCOS labeled patients, the mean of the variable (Y0-

279 mean) in the patients without the PCOS label, and the mean and standard deviation of the variable over all 280 patients (All-mean and All-SD). Ranking predictor variables by the absolute value of their coefficients in

- the logistic regression model amounts to ranking these variables by how much they affect the predicted probability of the outcome. A positive coefficient implies that the larger the value of the variable within the range specified by the data, the higher the chance of having a PCOS diagnosis as defined by the model outcome.
- 285

286 <u>Results</u>

287 Results of data acquisition and data pre-processing

288 After inclusion and exclusion criteria were applied to all 65,431 women within the initial data 289 pool, 30,601 patient records were available for this analysis and defined populations are included in 290 Figure 1. There were 1,329 patients (4.5%) with a PCOS ICD-9 diagnosis code (Model I). 1,465 patients 291 had records with PCOM results as present, absent, or unidentifiable. There were 1,056 patients (3.6%) 292 with undiagnosed PCOS (Model II), and a total of 1,116 (3.8%) of patients with no ICD 256.4 indication 293 and two out of IM/HA/PCOM positive criteria (Model III). Finally, there were 2,445 PCOS patients 294 (8.0%) in the combined analysis (Model IV). The total number of records in each model are included in 295 Supplementary Table 2. In the total cohort, the patients were predominantly Black/African American 296 (40.3%) and White (26.5%), with an average age of 33.6 years (SD = 6.6). Complete demographic 297 characteristics are described in Table 1.

There were 43 categorical variables and 12 continuous variables retained as predictors after the data pre-processing procedures. There were four pairs of highly correlated variables and one variable from each correlated pair included in the final model as noted in Supplemental Table 5. Supplementary

Table 4 describes all 51 variables used by the predictive models.

303 Model Performance

Tables 2, 3, 4 and 5 display the parsimonious models that use the MLP score (LR-L2-MLP score) and show the most significant variables in the prediction of the outcome for Models I, II, III, and IV, respectively. All p-values were less than 0.05, which was set as the significance level.

For Model I, the parsimonious predictive model achieved an AUC (SD) of 82.3% (1.7). The MLP score ($\beta = 0.71$) and obesity ($\beta = 0.45$) were positively correlated with PCOS diagnosis. Pregnancy (gravidity $\beta = -0.53$; positive pregnancy test $\beta = -0.50$), normal BMI ($\beta = -0.24$), smoking ($\beta = -0.18$), age ($\beta = -0.16$), and Hispanic race ($\beta = -0.10$) were inversely correlated with PCOS diagnosis as shown in Table 2.

312 For Model II, the parsimonious predictive model achieved an AUC (SD) of 77.6% (1.3). The 313 MLP score ($\beta = 0.61$), obesity ($\beta = 0.21$), normal BMI ($\beta = 0.15$), normal blood pressure ($\beta = 0.16$), negative pregnancy test ($\beta = 0.12$), and normal HDL ($\beta = 0.08$) were positively correlated with 314 315 undiagnosed PCOS. Age ($\beta = -0.27$), pregnancy (gravidity $\beta = -0.26$; positive pregnancy test $\beta = -0.19$), 316 and Hispanic race ($\beta = -0.18$) were inversely correlated with undiagnosed PCOS as show in Table 3. 317 For Model III, the parsimonious predictive model achieved an AUC (SD) of 77.4% (1.6). The 318 MLP score ($\beta = 0.60$), obesity ($\beta = 0.19$), normal blood pressure ($\beta = 0.17$), normal BMI ($\beta = 0.14$), Black 319 race (0.13), negative pregnancy test ($\beta = 0.12$), and normal HDL ($\beta = 0.09$) were positively correlated 320 with undiagnosed PCOS. Age ($\beta = -0.25$), pregnancy (gravidity $\beta = -0.24$; positive pregnancy test $\beta = -0.24$;

321 0.20), and Hispanic race ($\beta = -0.15$) were inversely correlated with undiagnosed PCOS as show in Table 322 4.

For Model IV, the parsimonious predictive model achieved an AUC (SD) of 79.1% (1.1). The MLP score ($\beta = 0.7$), obesity ($\beta = 0.31$), normal BMI ($\beta = 0.15$), hypertension ($\beta = 0.07$) and some higher degree of education, such as college or vocational/technical school ($\beta = 0.06$) were positively correlated with PCOS diagnosis. Age ($\beta = -0.21$), pregnancy (gravidity $\beta = -0.37$; positive pregnancy test $\beta = -0.34$; negative pregnancy test $\beta = -0.05$), Hispanic race ($\beta = -0.12$), and smoking ($\beta = -0.08$) were inversely correlated with PCOS diagnosis as shown in Table 5.

329 GBT models had the highest performance. Predictions of PCOS in a test set of patients not used 330 during algorithm training achieved 85%, 81%, 80%, and 82% AUC for Models I, II, III, and IV, 331 respectively. We also report the performance with the logistic regression model (LR-L1) after SFS and 332 the performance when using our developed MLP score alongside variables selected via recursive feature 333 elimination (LR-L2-MLP score). Supplementary Table 6 displays features for each model, associated 334 with LR-L1 algorithm after SFS. As we hypothesized, developing models using the MLP score (LR-L2-335 MLP score) leads to improvement of the performance of linear models (LR-L1) for Models I. II. III. and IV, respectively from 79%, 72%, 73%, and 75% AUC to 82%, 78%, 77%, and 79% AUC. Table 6 details 336 337 the models with the best performance (highest AUC) using all 51 features before and after statistical 338 feature selection (SFS). In Table 6, the means and standard deviations of AUC and weighted-F1 scores on 339 the test set over the five repetitions are listed. Supplementary Table 7 displays the performance of all

models and all algorithms, before and after statistical feature selection (SFS).

342 Discussion

343 Evaluating an at-risk population for PCOS is essential for early diagnosis and initiating multi-344 disciplinary care with the goal of reducing health risks (endometrial hyperplasia/cancer), infertility and 345 pregnancy complications, and chronic disease burden including cardiometabolic disorders associated with 346 PCOS. Retrospective analysis of the at-risk population within an urban health center allows for 347 assessment of factors predictive of diagnosis. Of note, the study sample represents a population of 348 patients who had any visit to BMC for primary care, obstetrics and gynecology, endocrinology, family 349 medicine, or general internal medicine and does not represent a random sample. While this is not a 350 population level assessment, our model is applicable to patients with high suspicion for PCOS who 351 interact with the healthcare system.

352 The ranked list of variables, from the most predictive to the least predictive of the PCOS 353 outcome, informed the main drivers of the predictive models. For example, non-gravidity, high levels of 354 LH, low levels of FSH, obesity, and higher BMI increase the likelihood of PCOS. These variables are 355 consistent with key variables from other models and in the pathophysiology of PCOS. The overall 356 predictive accuracy was high for all models, suggesting that a predictive model may assist in early 357 detection of PCOS within those at risk in an electronically interfaced medical record. Furthermore, we 358 found that non-linear models had superior predictive capacity compared to linear models for all four 359 model outcomes, potentially allowing for inclusion of non-linear reproductive hormone relationships.

360 When assessing patients who received a diagnosis of PCOS (Model I), the most predictive factors 361 related to diagnosis were hormone levels (as captured by the MLP score) and obesity, a clinical factor in 362 supporting a PCOS diagnosis. Specifically, there is a non-linear relationship between reproductive 363 hormones such as FSH, LH, and estradiol. Often these hormonal lab tests are obtained randomly in those 364 with oligomenorrhea, and it is also common to find an elevated FSH to LH ratio. A concern may also be 365 the misclassification of hypothalamic amenorrhea into the group classified as PCOS where the FSH and 366 LH levels would be low or suppressed, or in the setting of premature ovarian insufficiency, notable by an 367 elevated FSH and low estradiol. The MLP score allows for the diversity of relationships of these hormone levels and was trained using a neural network to appropriately classify PCOS. Additionally, prior 368 369 pregnancy (gravidity) and a positive pregnancy test were negatively associated with a diagnosis of PCOS, consistent with the underlying increased risk of infertility due to oligo-ovulation. Normal BMI and 370 371 smoking, a known ovarian toxicant, were negatively associated with the presence of a PCOS diagnosis,

372 which may indicate patient characteristics that increase risk of a delayed PCOS diagnosis. These

identified variables demonstrate the robustness of the model towards predicting phenotypic traits of

patients with PCOS, which is aligned with the performance accuracy. While the significant factors such

as hormone levels, gravidity, bHCG, and obesity identified in the model are already known to be
 associated with PCOS, the true impact of our model lies within the implementation of such a tool within

the EHR. For example, a real-world application of this model in the clinical setting would entail

378 integration of our model into the electronic health record system that would provide the probability of

379 PCOS diagnosis or set a threshold for suspicion for each patient to aid a provider's evaluation. This

380 would lead to more timely diagnosis and optimize referrals for downstream follow-up for known clinical 381 sequelae associated with PCOS.

382 When assessing patients who met diagnostic criteria without the ICD-9 label of PCOS (Models II 383 and III), predictive factors both supported the underlying PCOS diagnosis and alluded towards factors 384 that may contribute to missing the diagnosis despite meeting Rotterdam criteria. Similar to Model I, 385 gravidity and a positive pregnancy test were negatively associated with Models II and III diagnosis, while obesity was positively associated with Models II and III diagnosis, consistent with Model I. Interestingly, 386 387 distinct positive predictors among Models II and III were normal BMI, normal blood pressure, and 388 normal HDL. These patients may present as the "lean" phenotype of PCOS or those with mild features, 389 leading to underdiagnosis of PCOS. Diagnosing "lean" PCOS can be more nuanced, potentially delaying 390 diagnosis or requiring more specialized consultation (28). Within our cohort, 1,116 individuals were 391 identified by the model without the ICD-9 code that met Rotterdam PCOS diagnostic criteria (Model III), 392 suggesting the predictive value of our models to identify at risk groups within a large health system and 393 reduce delays in diagnosis. Given that women often wait over two years and see numerous health 394 professionals before receiving a diagnosis of PCOS, the integration of high-quality AI-based diagnostic 395 tools with the EHR could significantly contribute to more timely diagnosis (8).

396 Consistent with Models I. II, and III, positive pregnancy test and gravidity were both negatively 397 associated with PCOS diagnosis in Model IV while obesity and presence of hypertension were both 398 positively associated with the Model IV combined PCOS outcome. Some higher degree of education, 399 such as college or vocational/technical school, was also positively associated with the outcomes of 400 undiagnosed PCOS and combined PCOS (Models II, III, and IV), which may suggest that education 401 status and patient's self-advocacy for seeking care within a medical system may be implicated specifically 402 in under-diagnosed individuals. Of note, we dropped insurance status after finding that the null was a 403 strong predictor of PCOS, though it is interesting to note that 83% of 331 patients in this dataset with 404 missing insurance have PCOS. Insurance status alludes to socioeconomic barriers such as access to care, 405 which can result in a delay in timely diagnosis through either inability to seek evaluation or follow 406 through with testing. While the implications of insurance status and social determinants of health are 407 beyond the scope of this paper, it is important to note that persistence in seeking treatment within a 408 fractionated health care system can be challenging financially and psychologically, as patients may need 409 multiple evaluation or specialist's consultation to reach the right diagnosis.

410 A recent systematic review investigated the utility of artificial intelligence and machine learning in the diagnosis or classification of PCOS (29). Their search ultimately included 31 studies with sample 411 412 sizes ranging from 9 to 2,000 patients with PCOS. Methods employed by these models included support 413 vector machine, K-nearest neighbor, regression models, random forest, and neural networks. Only 19% of 414 included studies performed all major steps of training, testing, and validating their model. Furthermore, 415 only 32% of included studies used standardized diagnostic criteria such as the Rotterdam criteria or NIH criteria. The authors found that the ROC of included studies ranged from 73-100%. Only one study 416 417 sourced their data from electronic health records to build their model (30). Despite the lack of 418 standardized model training and diagnostic criteria used in these studies, the review concluded that 419 artificial intelligence and machine learning provide promise in detecting PCOS, allowing for an avenue 420 for early diagnosis.

421 Outside of the machine learning models included in the systematic review, other predictive 422 models have been created for earlier detection of PCOS as well as for predicting long-term health

423 outcomes among women with a diagnosis of PCOS. One such model was created from 11,720 ovarian 424 stimulation cycles at Peking University Third Hospital. The model used serum antimullerian hormone (AMH) and androstenedione levels, BMI, and menstrual cycle length to predict a diagnosis of PCOS. The 425 426 algorithm was then developed into an online platform that is able to calculate one's risk of PCOS given 427 certain indicators that are inputted into the model, allowing for better screening abilities in the clinic (31). 428 Another study created a similar model, taking into account AMH and BMI to predict a diagnosis of PCOS 429 or other ovulatory dysfunction disorders among 2,322 women (10). They found that in women with 430 higher BMIs and lower AMH levels could be used to predict PCOS compared to normal-weight or 431 underweight women. Deshmukh et al. created a simple four-variable model which included free androgen 432 index (FAI), 17-hydroxyprogesterone, AMH, and waist circumference for predicting risk of PCOS in a 433 cross-sectional study involving 111 women with PCOS and 67 women without PCOS (32). Lastly, Joo et 434 al. used polygenic and phenotypic risk scores to develop a PCOS risk prediction algorithm (33). They 435 found high degrees of association between PCOS and various metabolic and endocrine disorders 436 including obesity, type 2 diabetes, hypercholesterolemia, disorders of lipid metabolism, hypertension, and 437 sleep apnea (33).

438 In addition to the goal of improved screening for PCOS, models have been created to predict 439 long-term clinical outcomes in women with PCOS, such as ovulation, conception, and live birth (11,12). 440 Given the increased risk of insulin resistance in women with PCOS, Gennarelli et al. created a 441 mathematical model to predict insulin sensitivity based on variables such as BMI, waist and hip 442 circumferences, truncal-abdominal skin folds, and serum concentrations of androgens, SHBG, 443 triglycerides, and cholesterol (13). Models to predict non-alcoholic fatty liver disease risk among young 444 adults with PCOS have also been generated (34). Combining earlier detection with more accurate risk 445 stratification of clinical sequalae through predictive modeling can significantly improve the long-term 446 health outcomes of women with PCOS. Application of our models to predict other downstream health 447 risks after the diagnosis of PCOS is a future area of research.

448 Beyond the long-term health impacts of PCOS, the condition also carries a significant economic 449 cost for our healthcare system. A study by Riestenberg et al (2022) recently estimated the total economic 450 burden of PCOS, as well as the cost specifically for pregnancy-related complications and long-term health 451 morbidities (2). The authors estimated the annual economic burden of PCOS to be \$8 billion as of 2020 in 452 the United States. Furthermore, the excess cost of pregnancy-related comorbidities such as gestational 453 hypertension, gestational diabetes, and preeclampsia attributable to PCOS totals \$375 million USD 454 annually. Outside of pregnancy, the cost of long-term comorbidities associated with PCOS including 455 stroke and type 2 diabetes mellitus was estimated at \$3.9 billion USD. Meanwhile, the cost for diagnostic 456 evaluation of PCOS was less than 2% of the total economic burden. This estimated financial burden 457 suggests that predictive models aiding earlier diagnosis could not only reduce long-term health 458 consequences of PCOS but also alleviate significant healthcare costs associated with the condition.

459 Given the high prevalence, significant healthcare burden, and heterogeneity in clinical 460 presentation of PCOS. AI-based tools are well suited for earlier diagnosis of PCOS. Our study had many strengths. First, our machine learning models, which were highly accurate and robust in PCOS diagnosis 461 prediction, were created using the largest sample size to date (29). Second, our model was tested and 462 463 trained on a diverse Safety-Net hospital-sourced population not restricted to the context of fertility care. Third, it is the only model that incorporated three data streams (ICD-9 codes, clinical laboratory findings, 464 465 and radiologic findings) and an MLP score. Fourth, the parsimonious and interpretable models were very close in achieving full model predictive accuracy, performing relatively closely to the best-performing 466 non-linear models. Essentially, our parsimonious models "isolate" nonlinearities in hormone levels 467 468 (captured by the MLP score) and linearly combine that score with other variables. Most models evaluate 469 reproductive hormones (FSH, estradiol, LH, and SHBG) as individual variables within linear models, 470 which does not account for the high inter- and intra-patient variability. By using non-linear mapping of 471 the hormone values, we were able to generate a composite variable allowing for a linear function that correlates with the likelihood of an accurate prediction. Last, our variables are easily accessible in an 472 473 electronic health dataset, rendering the models helpful for clinical prediction. Our study did not evaluate

474 AMH as a predictive variable because it was not widely utilized during the time window of this data 475 extraction corresponding with ICD-9 codes.

Despite these strengths, our model is not without limitations. First, it is only directly applicable to 476

those who interact with the medical system and those deemed "at-risk" for a PCOS diagnosis, which 477

478 would not facilitate population-based prediction. Additional studies need to be conducted in other patient

479 populations or unselected community-based populations to validate the use of these models, especially

480 expanding to the entire population within a health system to evaluate the accuracy of our models (35).

481 Second, we must interpret our data within the limitations of informative presence in EHR data.

482 Informative presence is defined as data that is present and informed with respect to the health outcome, in

483 this case PCOS, as well as behavioral patterns of interaction with healthcare institutions which may be

additionally impacted by marginalization (36). This is an important consideration for interpreting 484 485 predictive models using EHR data (36,37). Nevertheless, we were able to extract over 1000 patients who

486 were undiagnosed with PCOS among the population, suggesting the predictive value of the modelling in

487 identifying diagnosis gaps among specific populations within a large health system. Third, it is possible

that additional examination of the medical record beyond ICD-9 diagnosis may allow for more 488

489 clarification of risk in the presumed PCOS group. Last, our exclusion of concurrent endocrinopathies was

490 chosen to avoid incorrectly including ovulation disorders caused by other endocrinopathies, but it is 491

possible that this was an overly strict exclusion criterion.

492 In conclusion, this novel machine learning algorithm incorporates three data streams from a large

493 EHR dataset to assess PCOS risk. This model can be integrated into the EHR to aid clinicians in earlier

494 diagnosis of PCOS and connect patients to interventions and healthcare providers across their

495 reproductive lifespan with the goal of health optimization and risk reduction.

496 Acknowledgements

497 We would like to acknowledge Linda Rosen, the research manager of the Clinical Data Warehouse at the

498 Boston Medical Center for procuring the dataset, and Alexis Veiga, the research assistant who provided 499 administrative support for this project.

500

501 Author contributions

- 502 ZZ performed the analysis and co-wrote the manuscript with a focus on the methods. VJ interpreted the
- 503 findings and drafted the initial manuscript. AW conducted a literature review, contributed to
- 504 interpretation of data, writing, and editing the manuscript. TW initiated the analytical approach to the
- 505 research question. JC curated the initial dataset and reviewed the analysis and manuscript drafts. SM and
- 506 ICP designed the study, oversaw analysis, interpretation of the findings, and manuscript drafting and
- 507 revision process. All authors met ICJME criteria for authorship.
- 508

509 Data availability

- 510 All datasets generated during and/or analyzed during the current study are not publicly available but are
- 511 available from the corresponding author on reasonable request.
- 512

513 **Competing interests**

514 The authors declare no competing interests.

515 **References**

- Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al.
 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456–88.
- Riestenberg C, Jagasia A, Markovic D, Buyalos RP, Azziz R. Health Care-Related Economic Burden of Polycystic Ovary Syndrome in the United States: Pregnancy-Related and Long-Term Health Consequences. J Clin Endocrinol Metab. 2022 Jan 18;107(2):575–85.
- 522 3. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin
 523 Epidemiol. 2013 Dec 18;6:1–13.
- 4. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with
 polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update.
 2014;20(5):748–58.
- 5. Lim SS, Kakoly NS, Tan JWJ, Fitzgerald G, Bahri Khomami M, Joham AE, et al. Metabolic syndrome
 in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev.
 2019;20(2):339–52.
- Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic
 consequences. Metabolism. 2018;86:33–43.
- 532 7. Wekker V, Van Dammen L, Koning A, Heida KY, Painter RC, Limpens J, et al. Long-term
 533 cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum
 534 Reprod Update. 2020;26(6):942–60.
- 8. Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information
 Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. J Clin Endocrinol
 Metab. 2017 Feb 1;102(2):604–12.
- 538
 9. Xu H, Feng G, Alpadi K, Han Y, Yang R, Chen L, et al. A Model for Predicting Polycystic Ovary
 539
 540 Syndrome Using Serum AMH, Menstrual Cycle Length, Body Mass Index and Serum
 540 Androstenedione in Chinese Reproductive Aged Population: A Retrospective Cohort Study. Front
 541 Endocrinol. 2022;13:821368.
- Vagios S, James KE, Sacha CR, Hsu JY, Dimitriadis I, Bormann CL, et al. A patient-specific model
 combining antimüllerian hormone and body mass index as a predictor of polycystic ovary syndrome
 and other oligo-anovulation disorders. Fertil Steril. 2021;115(1):229–37.
- 545 11. Kuang H, Jin S, Hansen KR, Diamond MP, Coutifaris C, Casson P, et al. Identification and replication
 546 of prediction models for ovulation, pregnancy and live birth in infertile women with polycystic ovary
 547 syndrome. Hum Reprod. 2015;30(9):2222–33.
- Jiang X, Liu R, Liao T, He Y, Li C, Guo P, et al. A Predictive Model of Live Birth Based on Obesity
 and Metabolic Parameters in Patients With PCOS Undergoing Frozen-Thawed Embryo Transfer. Front
 Endocrinol. 2021;12.
- 13. Gennarelli G, Holte J, Berglund L, Berne C, Massobrio M, Lithell H. Prediction models for insulin
 resistance in the polycystic ovary syndrome. Hum Reprod. 2000;15(10):2098–102.

- 14. Villarroel C, López P, Merino PM, Iñiguez G, Sir-Petermann T, Codner E. Hirsutism and
 oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents.
 Gynecol Endocrinol. 2015 Aug 3;31(8):625–9.
- 15. Monash University. International evidencebased guideline for the assessment and management ofpolycystic ovary syndrome. 2018.
- ESHRE TR, Group ASPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks
 related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
- 560 17. Cheng JJ, Mahalingaiah S. Data mining polycystic ovary morphology in electronic medical record 561 ultrasound reports. Fertil Res Pract. 2019;5(1):1–7.
- Hastie T, Tibshirani R, Friedman J. The elements of statistical learning: data mining, inference and
 prediction. Vol. 1. Springer series in statistics Springer, Berlin; 2001.
- 564 19. Chen R, Paschalidis IC. Distributionally Robust Learning. Found Trends® Optim. 2020 Dec 22;4(1–2):1–243.
- 566 20. Brisimi TS, Xu T, Wang T, Dai W, Adams WG, Paschalidis IC. Predicting Chronic Disease
 567 Hospitalizations from Electronic Health Records: An Interpretable Classification Approach. Proc
 568 IEEE. 2018 Apr;106(4):690–707.
- 569 21. Brisimi TS, Xu T, Wang T, Dai W, Paschalidis IC. Predicting diabetes-related hospitalizations based
 570 on electronic health records. Stat Methods Med Res. 2019 Dec 1;28(12):3667–82.
- 571 22. Chen R, Paschalidis ICh. Robust Grouped Variable Selection Using Distributionally Robust
 572 Optimization. J Optim Theory Appl. 2022 Sep 1;194(3):1042–71.
- 573 23. Chen R, Paschalidis IC, Hatabu H, Valtchinov VI, Siegelman J. Detection of unwarranted CT radiation
 574 exposure from patient and imaging protocol meta-data using regularized regression. Eur J Radiol Open.
 575 2019;6:206–11.
- 576 24. Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. In: Proceedings of the 22nd ACM
 577 SIGKDD International Conference on Knowledge Discovery and Data Mining [Internet]. San
 578 Francisco, California, USA: Association for Computing Machinery; 2016 [cited 2020 Jun 19]. p. 785–
 579 94. (KDD '16). Available from: https://doi.org/10.1145/2939672.2939785
- 580 25. Breiman L. Random forests. Mach Learn. 2001;45(1):5–32.
- 581 26. Ke G, Meng Q, Finley T, Wang T, Chen W, Ma W, et al. Lightgbm: A highly efficient gradient boosting
 582 decision tree. Adv Neural Inf Process Syst. 2017;30.
- Saito T, Rehmsmeier M. The Precision-Recall Plot Is More Informative than the ROC Plot When
 Evaluating Binary Classifiers on Imbalanced Datasets. Brock G, editor. PLOS ONE. 2015 Mar
 4;10(3):e0118432.
- Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical
 approach. J Diabetes Metab Disord. 2018 Nov 13;17(2):277–85.

- Barrera FJ, Brown EDL, Rojo A, Obeso J, Plata H, Lincango EP, et al. Application of machine learning
 and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a
 systematic review. Front Endocrinol [Internet]. 2023 [cited 2023 Sep 21];14. Available from:
 https://www.frontiersin.org/articles/10.3389/fendo.2023.1106625
- Son Castro V, Shen Y, Yu S, Finan S, Pau CT, Gainer V, et al. Identification of subjects with polycystic
 ovary syndrome using electronic health records. Reprod Biol Endocrinol RBE. 2015 Oct 29;13:116.
- 31. Xu H, Feng G, Alpadi K, Han Y, Yang R, Chen L, et al. A Model for Predicting Polycystic Ovary
 Syndrome Using Serum AMH, Menstrual Cycle Length, Body Mass Index and Serum
 Androstenedione in Chinese Reproductive Aged Population: A Retrospective Cohort Study. Front
 Endocrinol. 2022;13.
- 598 32. Deshmukh H, Papageorgiou M, Kilpatrick ES, Atkin SL, Sathyapalan T. Development of a novel risk
 599 prediction and risk stratification score for polycystic ovary syndrome. Clin Endocrinol (Oxf).
 600 2019;90(1):162–9.
- 33. Joo YY, Actkins K, Pacheco JA, Basile AO, Carroll R, Crosslin DR, et al. A polygenic and phenotypic
 risk prediction for polycystic ovary syndrome evaluated by phenome-wide association studies. J Clin
 Endocrinol Metab. 2020;105(6):1918–36.
- 604 34. Carreau AM, Pyle L, Garcia-Reyes Y, Rahat H, Vigers T, Jensen T, et al. Clinical prediction score of
 605 nonalcoholic fatty liver disease in adolescent girls with polycystic ovary syndrome (PCOS-HS index).
 606 Clin Endocrinol (Oxf). 2019;91(4):544–52.
- Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The Prevalence and Features of
 the Polycystic Ovary Syndrome in an Unselected Population. J Clin Endocrinol Metab. 2004 Jun
 1;89(6):2745–9.
- 610 36. Harton J, Mitra N, Hubbard RA. Informative presence bias in analyses of electronic health records611 derived data: a cautionary note. J Am Med Inform Assoc JAMIA. 2022 Jun 14;29(7):1191–9.
- 37. Sisk R, Lin L, Sperrin M, Barrett JK, Tom B, Diaz-Ordaz K, et al. Informative presence and observation
 in routine health data: A review of methodology for clinical risk prediction. J Am Med Inform Assoc
 JAMIA. 2020 Nov 9;28(1):155–66.

615





Variable	Model I	Model II	Model III	Model IV
Age, Mean years (SD)	33.6 (6.6)	33.7 (6.6)	33.7 (6.6)	33.6 (6.6)
Race, n (%)	1		1	1
Black/African American	11881 (40.3)	11824 (40.5)	11861 (40.5)	12395 (40.5)
White/Caucasian	7812 (26.5)	7733 (26.5)	7741 (26.4)	8086 (26.4)
Hispanic/Latina	2858 (9.7)	2837 (9.7)	2841 (9.7)	2929 (9.6)
Asian	1350 (4.6)	1354 (4.6)	1354 (4.6)	1406 (4.6)
Middle Eastern	175 (0.6)	176 (0.6)	176 (0.6)	184 (0.6)
American Indian/Native American	163 (0.6)	162 (0.6)	162 (0.6)	168 (0.5)
Native Hawaiian/Pacific Islander	17 (0.1)	18 (0.1)	18 (0.1)	18 (0.1)
Other	979 (3.3)	966 (3.3)	966 (3.3)	1023 (3.3)
Unknown	4250 (14.41)	4146 (14.19)	4153 (14.19)	4392 (14.4)
Marital Status				
Single	22325 (75.7)	22155 (75.8)	22199 (75.8)	23224 (75.9)
Married	5833 (19.8)	5753 (19.7)	5767 (19.7)	6018 (19.7)
Separated	392 (1.3)	391 (1.3)	392 (1.3)	401 (1.3)
Divorced	388 (1.3)	379 (1.3)	380 (1.3)	397 (1.3)
Widowed	35 (0.1)	35 (0.1)	35 (0.1)	35 (0.1)
Other	502 (1.7)	489 (1.7)	489 (1.7)	516 (1.7)
Unknown	10 (0.03)	10 (0.03)	10 (0.03)	10 (0.03)
Body Mass Index		2	-	
Normal (BMI < 25)	7534 (25.6)	7685 (26.3)	7697 (26.3)	7902 (25.8)
Overweight (BMI between 25-30)	5694 (19.3)	5689 (19.5)	5707 (19.5)	5941 (19.4)
Obese (BMI \geq 30)	7645 (25.9)	7369 (25.2)	7387 (25.2)	7985 (26.1)
Unknown	8612 (29.2)	8469 (29.0)	8481 (29.0)	8,773 (28.7)

Table 1. Demographic characteristics of the study population and by model.

Table 2. Most significant variables for PCOS diagnosis prediction in Model I.

Rank	Variables	β	β – %95 CI	Y- correlation	p-value	Y1- mean	Y0- mean	All- mean	All- std
					6.80E-				
0	MLP Score	0.71	0.028	0.33	197	0.17	0.04	0.05	0.08
1	Intercept	-0.68	-	-	-	-	-	-	-
2	Gravidity	-0.53	0.018	-0.12	4.55E-78	1.28	2.08	2.04	1.39

3	Positive bHCG	-0.5	0.019	-0.09	1.50E-48	0.05	0.23	0.22	0.42
4	Obesity	0.45	0.017	0.11	1.38E-81	0.51	0.27	0.28	0.45
5	Normal BMI	-0.24	0.017	-0.05	3.57E-16	0.15	0.26	0.26	0.44
6	Smoker	-0.18	0.017	-0.03	6.62E-05	0.09	0.14	0.14	0.34
7	Age	-0.16	0.016	-0.08	1.70E-25	31.34	33.79	33.68	6.61
8	Hispanic/Latina Race	-0.1	0.016	-0.02	1.82E-03	0.07	0.10	0.10	0.30

Table 3. Most significant variables for PCOS diagnosis prediction in Model II.

Rank	Variables	β	β - %95 CI	Y- correlation	p-value	Y1- mean	Y0- mean	All- mean	All- std
					2.13E-				
0	MLP Score	0.61	0.023	0.26	142	0.12	0.04	0.04	0.06
1	Intercept	-0.44	-	-	-	-	-	-	-
2	Age	-0.27	0.015	-0.08	2.26E-31	31.01	33.79	33.69	6.61
3	Gravidity	-0.26	0.016	-0.09	2.35E-63	1.42	2.08	2.06	1.39
4	Obesity	0.21	0.016	0.03	9.60E-06	0.34	0.27	0.27	0.44
5	Positive bHCG	-0.19	0.017	-0.06	4.14E-21	0.10	0.23	0.23	0.42
	Hispanic/Latina								
6	Race	-0.18	0.016	-0.02	2.69E-03	0.06	0.10	0.10	0.30
7	Normal BP	0.16	0.015	0.03	1.37E-07	0.60	0.51	0.51	0.50
8	Normal BMI	0.15	0.016	0.03	8.57E-07	0.34	0.26	0.26	0.44
9	Negative bHCG	0.12	0.015	0.06	1.44E-22	0.37	0.23	0.23	0.42
10	HDL	0.08	0.015	0.01	1.03E-10	52.13	51.59	51.61	7.86

Table 4. Most significant variables for PCOS diagnosis prediction in Model III.

Rank	Variables	β	β - %95 CI	Y- correlation	p-value	Y1- mean	Y0- mean	All- mean	All- std
0	MI P Score	0.6	0.023	0.26	7.41E-	0.10	0.04	0.04	0.05
1	Intercent	-	-		-	-	-	-	-
2	Age	-0.25	0.015	-0.08	5.91E-30	31.16	33.79	33.69	6.61
3	Gravidity	-0.24	0.016	-0.09	2.47E-63	1.46	2.08	2.06	1.39
4	Positive bHCG	-0.20	0.017	-0.06	3.59E-20	0.11	0.23	0.23	0.42
5	Obesity	0.19	0.016	0.03	2.73E-06	0.34	0.27	0.27	0.44
6	Normal BP	0.17	0.015	0.04	3.94E-08	0.60	0.51	0.51	0.50

7	Hispanic/Latina Race	-0.15	0.016	-0.02	2.00E-03	0.06	0.10	0.10	0.30
8	Normal BMI	0.14	0.016	0.03	6.76E-06	0.33	0.26	0.26	0.44
9	Black/African American Race	0.13	0.015	0.02	2.03E-03	0.46	0.40	0.41	0.49
10	Negative bHCG	0.12	0.015	0.06	2.20E-25	0.37	0.23	0.23	0.42
11	HDL	0.09	0.015	0.01	4.06E-12	52.04	51.59	51.61	7.86

Table 5. Most significant variables for PCOS diagnosis prediction in Model IV.

Rank	Variables	ß	β- %95 CI	Y- correlation	n-value	Y1- mean	Y0- mean	All- mean	All- std
INUITIN	v ur iusies	P	/0/2 01	correlation		mean	mean	meun	Stu
0	MLP Score	0.7	0.024	0.36	0.00E- 01	0.20	0.07	0.08	0.10
1	Intercept	-0.44	-	-	-	-	-	-	-
2	Gravidity	-0.37	0.017	-0.14	2.17E- 135	1.36	2.08	2.02	1.39
3	Positive bHCG	-0.34	0.017	-0.10	2.23E- 65	0.08	0.23	0.22	0.41
4	Obesity	0.31	0.015	0.10	2.86E- 66	0.43	0.27	0.28	0.45
5	Age	-0.21	0.015	-0.10	1.91E- 52	31.26	33.79	33.59	6.62
6	Hispanic/Latina Race	-0.12	0.015	-0.03	2.34E- 06	0.07	0.10	0.10	0.29
7	Smoker	-0.08	0.015	-0.02	3.00E- 04	0.11	0.14	0.14	0.34
8	Hypertension	0.07	0.015	0.04	3.63E- 12	0.28	0.21	0.22	0.41
9	Education – Some College/Technical/ Vocational School	0.06	0.014	0.03	1.55E- 04	0.18	0.15	0.15	0.36
10	Negative bHCG	-0.05	0.015	0.05	2.29E- 16	0.31	0.23	0.24	0.42

Table 6. Model performance over the test set, in the format of mean percentage (SD percentage) over 5 repetitions.

	Model I		Model II		Model III		Model IV		
	AUC	F1-weighted	AUC	F1-weighted	AUC	F1-weighted	AUC	F1-weighted	
Best full	Best full XGBoost (51 features)								
models before SFS	85.2 (1.8)	94.5 (0.2)	80.6 (0.5)	95.1 (0.2)	80.4 (0.7)	94.8 (0.1)	81.8 (1.4)	91.1 (0.4)	
Best full	XGBoost (14 features)		XGBoost (16 features)		XGBoost (17 features)		XGBoost (17 features)		
models after SFS	83.6 (1.7)	94.5 (0.2)	80.5 (0.7)	95.1 (0.2)	79.8 (1.1)	94.8 (0.1)	81.1 (1.3)	90.9 (0.3)	

LR-L1 (14 features)		LR-L1 (16 features)		LR-L1 (17 features)	LR-L1 (17 features)	
79.2 (1.9)	93.9 (0.2)	71.7 (0.9)	94.7 (0.1)	72.9 (2.1)	94.4 (0.1)	74.8 (1.1)	89.7 (0.3)
Parsi m LR-L2-M fea	Parsimonious models LR-L2-MLP score (8 features)		Parsimonious models LR-L2-MLP score (10 features)		Parsimonious models LR-L2-MLP score (11 features)		monious odels LP score (10 ttures)
82.3 (1.7)	94.5 (0.1)	77.6 (1.3)	95.1 (0.1)	77.4 (1.6)	94.9 (0.1)	79.1 (1.1)	90.8 (0.3)